68.09

1.00% -0.69

Pre-market: 68.67 0.58 +0.85%

Bridgebio Pharma Inc (BBIO)

Overview News Price History Option Chain Financials Why BBIO Down? Discussions Forecast

Bridgebio Pharma Inc stock is traded at $68.09, with a volume of 2.64M. It is down -1.00% in the last 24 hours and down -5.80% over the past month. BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Previous Close:

$68.78

Open:

$68.74

24h Volume:

2.64M

Relative Volume:

0.99

Market Cap:

$13.20B

Revenue:

$502.08M

Net Income/Loss:

$-732.94M

P/E Ratio:

-17.99

EPS:

-3.7842

Net Cash Flow:

$-455.50M

1W Performance:

-4.02%

1M Performance:

-5.80%

6M Performance:

+8.54%

1Y Performance:

+84.33%

1-Day Range:

$67.92

$69.39

1-Week Range:

$67.48

$72.49

52-Week Range:

$31.77

$84.94

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name

Bridgebio Pharma Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(650) 391-9740

Address

3160 PORTER DR., PALO ALTO, CA

Employee

839

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

BBIO's Discussions on Twitter

Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BBIO Bridgebio Pharma Inc	68.09	13.20B	502.08M	-732.94M	-455.50M	-3.7842
VRTX Vertex Pharmaceuticals Inc	427.65	108.54B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	75.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	50.22B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.45B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	32.51B	5.36B	287.73M	924.18M	2.5229

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	RBC Capital Mkts	Outperform
Mar-10-26	Initiated	William Blair	Outperform
Jan-28-26	Initiated	Barclays	Overweight
Jan-06-26	Initiated	Morgan Stanley	Overweight
Dec-11-25	Initiated	Bernstein	Outperform
Jul-30-25	Resumed	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Jul-14-25	Initiated	Jefferies	Buy
Jul-09-25	Upgrade	Oppenheimer	Perform → Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Mar-31-25	Initiated	Redburn Atlantic	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight
Mar-21-24	Resumed	Raymond James	Outperform
Jan-31-24	Initiated	BMO Capital Markets	Market Perform
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Jul-18-23	Downgrade	Jefferies	Buy → Hold
Apr-19-23	Initiated	Evercore ISI	Outperform
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	Mizuho	Buy
Dec-27-21	Reiterated	SVB Leerink	Outperform
Sep-10-21	Upgrade	BofA Securities	Neutral → Buy
May-21-21	Initiated	UBS	Buy
Mar-22-21	Reiterated	Goldman	Buy
Feb-22-21	Resumed	JP Morgan	Overweight
Feb-09-21	Resumed	Goldman	Buy
Jan-11-21	Reiterated	H.C. Wainwright	Buy
Dec-10-20	Reiterated	H.C. Wainwright	Buy
Jun-25-20	Initiated	BofA/Merrill	Neutral
May-19-20	Initiated	BTIG Research	Buy
Apr-13-20	Initiated	H.C. Wainwright	Buy
Feb-19-20	Initiated	Mizuho	Buy
Jul-26-19	Initiated	Raymond James	Outperform
Jul-22-19	Initiated	BMO Capital Markets	Outperform
Jul-22-19	Initiated	Goldman	Buy
Jul-22-19	Initiated	JP Morgan	Overweight
Jul-22-19	Initiated	Jefferies	Buy
Jul-22-19	Initiated	Piper Jaffray	Overweight
Jul-22-19	Initiated	SVB Leerink	Outperform

View All

Bridgebio Pharma Inc Stock (BBIO) Latest News

May 06, 2026

A Look At BridgeBio Pharma (BBIO) Valuation After Recent Trading Weakness And Pipeline Expectations - Yahoo Finance

May 06, 2026

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil - Yahoo Finance

May 06, 2026

BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN

May 06, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 06, 2026

May 05, 2026

BridgeBio to present encaleret data at endocrinology congress By Investing.com - Investing.com South Africa

May 05, 2026

BridgeBio to present encaleret data at endocrinology congress - Investing.com UK

May 05, 2026

BridgeBio Pharma to Present Phase 3 Infigratinib Achondroplasia Trial Results at ECE 2026, Focusing on Annualized Growth Velocity in Children Aged 3-11 - geneonline.com

May 05, 2026

MSN Money - MSN

May 05, 2026

BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE - The Manila Times

May 05, 2026

BridgeBio to unveil Phase 3 rare-disease trial results in Prague - Stock Titan

May 05, 2026

BBIO SEC FilingsBridgebio Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

May 05, 2026

May 04, 2026

[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan

May 04, 2026

Achondroplasia Pipeline Expands as 15+ Pharma Companies - openPR.com

May 04, 2026

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 - The Manila Times

May 04, 2026

New heart failure data on BridgeBio drug lands late-breaking ESC slot - Stock Titan

May 04, 2026

May 03, 2026

William Blair Initiates BridgeBio Pharma(BBIO.US) With Buy Rating - Moomoo

May 03, 2026

May 02, 2026